Voskresensky Igor, Scali Salvatore T, Feezor Robert J, Fatima Javairiah, Giles Kristina A, Tricarico Rosamaria, Berceli Scott A, Beck Adam W
Division of Vascular Surgery and Endovascular Therapy, University of Florida College of Medicine, Gainesville, Fla.
Division of Vascular Surgery and Endovascular Therapy, University of Florida College of Medicine, Gainesville, Fla.
J Vasc Surg. 2017 Jul;66(1):9-20.e3. doi: 10.1016/j.jvs.2016.11.063.
Aortic arch disease is a challenging clinical problem, especially in high-risk patients, in whom open repair can have morbidity and mortality rates of 30% to 40% and 2% to 20%, respectively. Aortic arch chimney (AAC) stents used during thoracic endovascular aortic repair (TEVAR) are a less invasive treatment strategy than open repair, but the current literature is inconclusive about the role of this technology. The focus of this analysis is on our experience with TEVAR and AAC stents.
All TEVAR procedures performed from 2002 to 2015 were reviewed to identify those with AAC stents. Primary end points were technical success and 30-day and 1-year mortality. Secondary end points included complications, reintervention, and endoleak. Technical success was defined as a patient's surviving the index operation with deployment of the AAC stent at the intended treatment zone with no evidence of type I or type III endoleak on initial postoperative imaging. The Kaplan-Meier method was used to estimate survival.
Twenty-seven patients (age, 69 ± 12 years; male, 70%) were identified, and all were described as being at prohibitive risk for open repair by the treating team. Relevant comorbidity rates were as follows: coronary artery disease/myocardial infarction, 59%; oxygen-dependent emphysema, 30%; preoperative creatinine concentration >1.8 mg/dL, 19%; and congestive heart failure, 15%. Presentations included elective (67%; n = 18), symptomatic (26%; n = 7), and ruptured (7%; n = 2). Eleven patients (41%) had prior endovascular or open arch/descending thoracic repair. Indications were degenerative aneurysm (49%), chronic residual type A dissection with aneurysm (15%), type Ia endoleak after TEVAR (11%), postsurgical pseudoaneurysm (11%), penetrating ulcer (7%), and acute type B dissection (7%). Thirty-two brachiocephalic vessels were treated: innominate (n = 7), left common carotid artery (LCCA; n = 24), and left subclavian artery (n = 1). Five patients (19%) had simultaneous innominate-LCCA chimneys. Brachiocephalic chimney stents were planned in 75% (n = 24), with the remainder placed for either LCCA or innominate artery encroachment (n = 8). Overall technical success was 89% (one intraoperative death, two persistent type Ia endoleaks in follow-up). The 30-day mortality was 4% (n = 1; intraoperative death of a patient with a ruptured arch aneurysm), and median length of stay was 6 (interquartile range, 4-9) days. Seven (26%) patients experienced a major complication (stroke, three [all with unplanned brachiocephalic chimney]; respiratory failure, three; and death, one). Nine (33%) patients underwent aorta-related reintervention, and no chimney occlusion events occurred during follow-up (median follow-up, 9 [interquartile range, 1-23] months). The 1-year and 3-year survival is estimated to be 88% ± 6% and 69% ± 9%, respectively.
TEVAR with AAC can be performed with high technical success and acceptable morbidity and mortality in high-risk patients. Unplanned AAC placement during TEVAR results in an elevated stroke risk, which may be related to the branch vessel coverage necessitating AAC placement. Acceptable midterm survival can be anticipated, but aorta-related reintervention is not uncommon, and diligent follow-up is needed.
主动脉弓疾病是一个具有挑战性的临床问题,尤其在高危患者中,开放修复的发病率和死亡率分别可达30%至40%和2%至20%。在胸主动脉腔内修复术(TEVAR)中使用的主动脉弓烟囱(AAC)支架是一种比开放修复侵入性更小的治疗策略,但目前的文献对于该技术的作用尚无定论。本分析的重点是我们在TEVAR和AAC支架方面的经验。
回顾了2002年至2015年期间所有的TEVAR手术,以确定使用AAC支架的手术。主要终点是技术成功率、30天和1年死亡率。次要终点包括并发症、再次干预和内漏。技术成功定义为患者在索引手术中存活,且在预期治疗区域部署了AAC支架,术后初始影像检查未发现I型或III型内漏。采用Kaplan-Meier法估计生存率。
共确定了27例患者(年龄69±12岁;男性占70%),治疗团队均认为所有患者进行开放修复的风险极高。相关合并症发生率如下:冠状动脉疾病/心肌梗死,59%;依赖氧气的肺气肿,30%;术前肌酐浓度>1.8mg/dL,19%;充血性心力衰竭,15%。临床表现包括择期手术(67%;n = 18)、有症状(26%;n = 7)和破裂(7%;n = 2)。11例患者(41%)曾接受过血管腔内或开放的主动脉弓/降主动脉修复术。适应证包括退行性动脉瘤(49%)、慢性A型夹层伴动脉瘤残留(15%)、TEVAR术后Ia型内漏(11%)、术后假性动脉瘤(11%)、穿透性溃疡(7%)和急性B型夹层(7%)。共治疗了32支头臂血管:无名动脉(n = 7)、左颈总动脉(LCCA;n = 24)和左锁骨下动脉(n = 1)。5例患者(19%)同时进行了无名动脉-LCCA烟囱支架置入。75%(n = 24)的患者计划置入头臂烟囱支架,其余患者因LCCA或无名动脉受压而置入(n = 8)。总体技术成功率为89%(1例术中死亡,随访中2例持续存在Ia型内漏)。30天死亡率为4%(n = 1;1例弓部动脉瘤破裂患者术中死亡),中位住院时间为6天(四分位间距,4 - 9天)。7例患者(26%)发生了严重并发症(卒中3例[均为意外置入头臂烟囱支架];呼吸衰竭3例;死亡1例)。9例患者(33%)接受了与主动脉相关的再次干预,随访期间未发生烟囱闭塞事件(中位随访时间9个月[四分位间距,1 - 23个月])。估计1年和3年生存率分别为88%±6%和69%±9%。
在高危患者中,采用AAC的TEVAR技术成功率高,发病率和死亡率可接受。TEVAR术中意外置入AAC会增加卒中风险,这可能与因需要置入AAC而覆盖分支血管有关。中期生存率可接受,但与主动脉相关的再次干预并不少见,需要进行密切随访。